{"gene":"CHCHD10","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2014,"finding":"CHCHD10 is a mitochondrial protein localized to the intermembrane space and enriched at cristae junctions; overexpression of the S59L mutant allele in HeLa cells causes fragmentation of the mitochondrial network and major ultrastructural abnormalities including loss, disorganization and dilatation of cristae.","method":"Immunofluorescence, subcellular fractionation, overexpression in HeLa cells with mitochondrial network imaging","journal":"Brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiment with functional consequence, replicated across multiple subsequent studies; original discovery paper with multiple orthogonal methods","pmids":["24934289"],"is_preprint":false},{"year":2016,"finding":"CHCHD10 resides within the MICOS (mitochondrial contact site and cristae organizing system) complex together with mitofilin, CHCHD3, and CHCHD6; CHCHD10 mutations lead to MICOS complex disassembly, loss of mitochondrial cristae, decreased nucleoid number and disorganization, impaired mtDNA repair after oxidative stress, and inhibition of apoptosis by preventing cytochrome c release.","method":"Co-immunoprecipitation, patient fibroblast analysis, immunofluorescence, electron microscopy, apoptosis assays","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying MICOS complex membership, multiple orthogonal functional assays, replicated in subsequent studies","pmids":["26666268"],"is_preprint":false},{"year":2018,"finding":"CHCHD10 localizes to the mitochondrial intermembrane space where it physically interacts with CHCHD2 and with p32/GC1QR; CHCHD10 and CHCHD2 have short half-lives suggesting regulatory rather than structural functions; CHCHD10 knockdown causes accumulation of excessive intramitochondrial iron but no bioenergetic defects; cells expressing S59L or R15L mutant CHCHD10 (but not WT) show impaired mitochondrial energy metabolism, supporting a gain-of-toxic-function mechanism.","method":"Co-immunoprecipitation, mass spectrometry interactome, CHCHD10 knockdown cell lines, metabolic assays, mouse tissue expression analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus MS interactome, KD with defined cellular phenotype, multiple orthogonal methods in single study","pmids":["29112723"],"is_preprint":false},{"year":2018,"finding":"The p.R15L CHCHD10 variant in ALS patient fibroblasts destabilizes the protein, causing defective assembly of Complex I, impaired cellular respiration, mitochondrial hyperfusion, and increased CHCHD2 levels; CHCHD10 and CHCHD2 co-immunoprecipitate quantitatively and co-migrate in a ~220 kDa high-molecular-weight complex by BN-PAGE, which is absent in patient cells.","method":"Blue native PAGE, reciprocal co-immunoprecipitation, oxygen consumption assays, patient fibroblasts","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, BN-PAGE complex analysis, patient cells with functional readout, multiple orthogonal methods","pmids":["29121267"],"is_preprint":false},{"year":2018,"finding":"CHCHD10 and CHCHD2 are similarly distributed throughout mitochondrial cristae and form heterodimers; CHCHD2 is preferentially stabilized by loss of mitochondrial membrane potential, and CHCHD10 oligomerization depends on CHCHD2 expression; disease-causing mutations in both proteins still readily form heterodimers.","method":"CHCHD2/CHCHD10 double knockout cell lines, co-immunoprecipitation, immunofluorescence, mitochondrial stress treatments","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — knockout cell lines with reciprocal Co-IP, multiple orthogonal methods including stress-response assays","pmids":["30084972"],"is_preprint":false},{"year":2018,"finding":"CHCHD10 mitochondrial import is mediated by the CHCH domain rather than the proposed N-terminal mitochondrial targeting signal; mitochondrial import of CHCHD10 depends on Mia40, which introduces disulfide bonds into CHCH domain proteins; the ALS-associated Q108P mutation nearly completely blocks mitochondrial import, causing diffuse cytoplasmic localization; overexpression of Mia40 rescues mitochondrial import of CHCHD10 Q108P by enhancing disulfide-bond formation.","method":"Truncation experiments, Mia40 knockdown and overexpression, subcellular fractionation, immunofluorescence","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (truncation analysis, KD/OE rescue), defined mechanistic finding about import pathway","pmids":["29789341"],"is_preprint":false},{"year":2018,"finding":"CHCHD10 co-purifies with cytochrome c oxidase (COX) and up-regulates COX activity by serving as a scaffolding protein required for MNRR1 (CHCHD2) phosphorylation mediated by ABL2; in the nucleus, CHCHD10 down-regulates expression of genes with oxygen-responsive elements (ORE) by interacting with and augmenting the transcriptional repressor CXXC5; disease variants G66V and P80L show faulty interactions with MNRR1 and COX, reducing respiration and increasing ROS, and abrogate transcriptional repression.","method":"Co-purification with COX, nuclear fractionation, transcriptional reporter assays, co-immunoprecipitation with CXXC5, respiration and ROS assays","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-purification and nuclear interaction data from single lab; multiple methods but not independently replicated","pmids":["29540477"],"is_preprint":false},{"year":2019,"finding":"CHCHD10 S55L (equivalent to human S59L) knock-in mice accumulate CHCHD10 in aggregates together with paralog CHCHD2 specifically in affected tissues, leading to aberrant organelle morphology; these aggregates induce a potent mitochondrial integrated stress response (mtISR) through mTORC1 activation with elevation of stress-induced transcription factors, secretion of myokines, upregulated serine and one-carbon metabolism, and downregulation of respiratory chain enzymes; CHCHD10 ablation does not induce disease pathology or activate mtISR, establishing a gain-of-toxic-function mechanism.","method":"Knock-in mouse model, immunofluorescence/immunohistochemistry, proteomic and transcriptomic analyses, metabolic assays, knockout comparison","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in and knockout mouse models compared, multiple omics approaches, defined cellular phenotype with pathway placement","pmids":["30877432"],"is_preprint":false},{"year":2020,"finding":"Loss of both CHCHD2 and CHCHD10 activates the OMA1 metallopeptidase, which cleaves long-form OPA1 (L-OPA1), causing disrupted mitochondrial cristae; OMA1 activation similarly occurs in affected tissues of mutant CHCHD10 knock-in mice; using OMA1 activation as a functional assay, CHCHD2 and CHCHD10 are found to be partially functionally redundant.","method":"CHCHD2/CHCHD10 double knockout mice, knock-in mice, OPA1 cleavage assays, OMA1 activity assays, electron microscopy","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — double knockout and knock-in mouse models, mechanistic pathway identified (OMA1-OPA1 axis), multiple orthogonal methods","pmids":["32338760"],"is_preprint":false},{"year":2022,"finding":"In physiological conditions, CHCHD2 and CHCHD10 interact with OMA1 and suppress its enzyme activity, restraining initiation of the mitochondrial integrated stress response (mtISR) and suppressing OPA1 processing for mitochondrial fusion; during mitochondrial stress (CCCP treatment), CHCHD2 and CHCHD10 translocate to the cytosol and interact with eIF2α, attenuating mtISR overactivation by suppressing eIF2α phosphorylation.","method":"Co-immunoprecipitation with OMA1, OMA1 enzymatic assay, subcellular fractionation under stress, eIF2α phosphorylation assays, knockdown experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and functional enzymatic assay from single lab; translocation experiment adds orthogonal evidence but not independently replicated","pmids":["35173147"],"is_preprint":false},{"year":2022,"finding":"CHCHD10 interacts with Stomatin-Like Protein 2 (SLP2) and participates in stability of the prohibitin (PHB) complex in the inner mitochondrial membrane; the S59L mutation causes SLP2 and prohibitin to form aggregates in patient fibroblasts and in vivo in spinal motor neurons; PHB complex destabilization activates the OMA1 cascade with OPA1 processing leading to mitochondrial fragmentation and abnormal cristae morphogenesis.","method":"Co-immunoprecipitation, patient fibroblasts, CHCHD10S59L/+ knock-in mice, immunohistochemistry, electron microscopy","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus knock-in mouse model with in vivo validation, multiple orthogonal methods from single lab","pmids":["35656794"],"is_preprint":false},{"year":2022,"finding":"OMA1-mediated stress response is critical for survival of CHCHD10 G58R knock-in mice; mutant CHCHD10 aggregates apply toxic protein stress to the inner mitochondrial membrane; OMA1 acts both locally (causing mitochondrial fragmentation) and signals outside mitochondria by cleaving DELE1 to activate the integrated stress response (ISR); an isoform switch in terminal electron transport chain complex is also identified as part of this response.","method":"CHCHD10 G58R knock-in mouse model, genetic ablation of OMA1, DELE1 cleavage assay, transcriptomic and proteomic analysis, electron microscopy","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knock-in model with OMA1 genetic ablation as epistasis test, DELE1 cleavage mechanistically demonstrated, multiple orthogonal methods","pmids":["35700042"],"is_preprint":false},{"year":2017,"finding":"Loss of function of endogenous CHCHD10 impairs mitochondrial and synaptic integrity and promotes cytoplasmic TDP-43 accumulation; FTD/ALS-associated mutations R15L and S59L exhibit loss-of-function phenotypes in C. elegans genetic complementation assays and dominant negative activities in mammalian systems, causing mitochondrial/synaptic damage and cytoplasmic TDP-43 accumulation.","method":"C. elegans genetic complementation, mammalian cell lines, primary neurons, mouse brains; loss-of-function and mutant overexpression with TDP-43 localization readouts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in C. elegans, multiple model systems (worm, mammalian cells, neurons, mouse), multiple orthogonal readouts","pmids":["28585542"],"is_preprint":false},{"year":2020,"finding":"CHCHD10 knockdown causes disassembly of OPA1-mitofilin complexes in brain; TDP-43 overexpression reduces CHCHD10 levels and promotes OPA1-mitofilin complex disassembly via CHCHD10, impairing mitochondrial fusion and respiration; wild-type CHCHD10 rescues TDP-43-induced OPA1-mitofilin complex disassembly and mitochondrial defects.","method":"CHCHD10 knockdown, TDP-43 overexpression, co-immunoprecipitation of OPA1-mitofilin complexes, mitochondrial fusion assays, respiration assays, transgenic mice, FTLD-TDP patient brains","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue experiment, multiple model systems, single lab","pmids":["32369233"],"is_preprint":false},{"year":2020,"finding":"CHCHD10 is required for ATP production in skeletal muscle, which in turn facilitates acetylcholine receptor (AChR) expression and promotes agrin-induced AChR clustering at neuromuscular junctions; ATP addition rescues the reduction of AChR clusters in CHCHD10-ablated muscles.","method":"Muscle conditional knockout mice, ATP rescue experiment, AChR clustering assay, electrophysiology","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific rescue by ATP, mechanistic pathway defined, single lab","pmids":["31261376"],"is_preprint":false},{"year":2021,"finding":"The CHCHD10 R15L variant causes a complex I deficiency that increases the NADH/NAD+ ratio, diminishes TCA cycle activity, reorganizes one-carbon metabolism, raises AMP/ATP ratio leading to AMPK phosphorylation and mTORC1 inhibition; these metabolic changes activate the UPR in the ER through IRE1/XBP1 and the mitochondrial UPR via ATF4/ATF5 upregulation.","method":"Multi-omics (transcriptomics, metabolomics, proteomics) in patient cells under energetic stress","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omics integration with functional pathway mapping, single lab, patient cells","pmids":["33749723"],"is_preprint":false},{"year":2021,"finding":"CHCHD10 S59L mutation in Drosophila and HeLa cells increases TDP-43 insolubility and mitochondrial translocation; blocking TDP-43 mitochondrial translocation with a peptide inhibitor reduces CHCHD10 S59L-mediated toxicity; CHCHD10 S59L also chronically activates the PINK1 pathway, and genetic/pharmacological modulation of PINK1 rescues CHCHD10 S59L-induced phenotypes.","method":"Drosophila model, HeLa cell model, peptide inhibitor of TDP-43 translocation, PINK1 genetic and pharmacological manipulation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple model systems (Drosophila and human cells), genetic epistasis with PINK1, peptide inhibitor rescue experiment, multiple orthogonal methods","pmids":["33772006"],"is_preprint":false},{"year":2023,"finding":"CHCHD10 mutations (R15L and S59L) reduce PINK1 levels by increasing PARL protease activity, whereas wild-type CHCHD10 suppresses PARL activity through direct interaction, thereby promoting PINK1 stability and mitophagy flux; CHCHD10 mutations impair mitochondrial Parkin recruitment and mitophagy flux, and impaired mitophagy promotes TDP-43 aggregation.","method":"In vivo and in vitro models, PARL activity assays, co-immunoprecipitation of CHCHD10-PARL, mitophagy flux assays, Parkin recruitment assays, human FTD brain tissue","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP defining CHCHD10-PARL interaction, PARL activity assay, mitophagy functional readout, single lab with in vivo and human tissue validation","pmids":["38132101"],"is_preprint":false},{"year":2010,"finding":"CHCHD10 plays a role in complex IV (cytochrome c oxidase) activity, confirmed by gene knockdown in vitro.","method":"siRNA knockdown, complex IV activity assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single functional assay with knockdown, single lab, but later replicated by other groups","pmids":["20888800"],"is_preprint":false},{"year":2018,"finding":"The p.R15L and p.G66V CHCHD10 mutations cause haploinsufficiency: CHCHD10 protein levels are reduced to ~50% in patient cells (p.R15L at the mRNA level; p.G66V through altered secondary structure and rapid protein degradation); knockdown of CHCHD10 in zebrafish to ~50% causes motoneuron pathology, abnormal myofibrillar structure and motility deficits in vivo.","method":"Patient fibroblast protein/mRNA quantification, secondary structure analysis, zebrafish knockdown model with behavioral and histological readouts","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient cell biochemistry combined with zebrafish in vivo model, multiple orthogonal methods, single lab","pmids":["29315381"],"is_preprint":false},{"year":2019,"finding":"CHCHD10 S59L/+ knock-in mice develop OXPHOS deficiency in muscle at 3 months, prior to neuromuscular junction fragmentation and motor neuron loss, establishing that the pathological effects of the mutation target muscle before NMJ and motor neurons; CHCHD10 is highly expressed at the NMJ postsynaptic part and S59L mutation causes abnormal CHCHD10 expression at motor end plates.","method":"CHCHD10 S59L/+ knock-in mice, temporal histopathological analysis, OXPHOS enzyme histochemistry, motor neuron counting, NMJ morphology assessment, iPSC-derived motor neurons","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse model with temporal dissection of pathology, multiple cell/tissue types, epistatic ordering of pathological events","pmids":["30874923"],"is_preprint":false},{"year":2019,"finding":"CHCHD2 T61I mutation causes increased interaction with CHCHD10 and reduced CHCHD10 protein levels; mitochondrial ultrastructural alterations in CHCHD2 T61I patient fibroblasts are similar to those caused by CHCHD10 mutations, implicating CHCHD10 in CHCHD2-related Parkinson's disease pathogenesis.","method":"Co-immunoprecipitation in patient fibroblasts, Western blot quantification, electron microscopy","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP in patient cells plus ultrastructural phenotyping, single lab, multiple orthogonal methods","pmids":["30530185"],"is_preprint":false},{"year":2022,"finding":"CHCHD10 deficiency leads to disorganization of mitochondrial cristae, impairment of OXPHOS complex assembly, inhibition of ATP generation, and downregulation of lipolysis through reduced ATGL protein synthesis; augmented lipolysis by ATGL overexpression restores thermogenesis in adipocyte-specific Chchd10 knockout mice.","method":"Adipocyte-specific conditional knockout mice, ATGL overexpression rescue, OXPHOS complex assembly assay, ATP measurement, lipolysis assay","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with ATGL overexpression rescue defining mechanistic pathway, single lab","pmids":["35709007"],"is_preprint":false},{"year":2022,"finding":"During myogenesis, CHCHD10 interacts with TDP-43 in regenerating myofibers and newly differentiated myotubes; Chchd10 knockout mice have normal skeletal muscle development but blunted cold-induced browning of white adipose tissue with markedly reduced UCP1, indicating CHCHD10 is required for cold-induced, mitochondrion-dependent browning.","method":"Co-immunoprecipitation in vivo and ex vivo, Chchd10 knockout mice, cold challenge assay, UCP1 Western blot","journal":"Cell regeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo Co-IP combined with KO mouse cold challenge, single lab","pmids":["35362877"],"is_preprint":false},{"year":2022,"finding":"CHCHD10 S59L mutant knock-in mouse hearts show an extensive metabolic rewiring triggered by proteotoxic mtISR before bioenergetic impairment onset: a switch from oxidative to glycolytic metabolism, enhancement of transsulfuration and one-carbon metabolism, and increased NADPH oxidases activating antioxidant responses with heme depletion.","method":"CHCHD10 S55L knock-in mouse model, metabolomics, transcriptomics, metabolic flux analysis, temporal disease staging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse model, multi-omics with temporal staging establishing metabolic rewiring precedes OXPHOS dysfunction, multiple orthogonal methods","pmids":["35263592"],"is_preprint":false},{"year":2022,"finding":"CHCHD10 S59L mutation induces aggregation of resident CHCHD10 protein in isolated mitochondria and simultaneously enhances aggregation of recombinant TDP-43 imported into mitochondria; wild-type CHCHD10 inhibits the growth of TDP-43 aggregates in an in vitro cell-free system, as demonstrated by filter trap assay and atomic force microscopy.","method":"In vitro cell-free aggregation assay, isolated mitochondria, filter trap assay, atomic force microscopy, transgenic mice, human brain tissue","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 1/2 / Moderate — in vitro reconstitution of aggregation, AFM structural validation, multiple model systems, single lab","pmids":["35787294"],"is_preprint":false},{"year":2024,"finding":"CHCHD10 amyloid fibrils formed by the disordered N-terminal domain of CHCHD10 have a cryoEM-resolved structure; disease-associated mutations cannot be accommodated by the WT fibril structure, whereas sequence differences between CHCHD10 and CHCHD2 are tolerated, explaining co-aggregation of the two proteins.","method":"CryoEM structure determination of amyloid fibrils formed by N-terminal domain of CHCHD10","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryoEM structure of amyloid fibrils with mutant compatibility analysis; single lab but rigorous structural method","pmids":[],"is_preprint":true},{"year":2025,"finding":"Mutant CHCHD10 S55L causes impaired mitochondrial copper homeostasis and defective cytochrome c oxidation as an early bioenergetic defect; defective respiration in mutant mitochondria is rescued by exogenous addition of cytochrome c, pinpointing IMS proteostasis disruption affecting cytochrome c biogenesis as a key pathogenic mechanism; OMA1 catalytic inactivation in Chchd10 S55L/+ mice delays cardiomyopathy onset without rescuing CHCHD10 insolubility, cristae defects or OXPHOS impairment, demonstrating mtISR can be uncoupled from bioenergetic collapse.","method":"CHCHD10 S55L knock-in mice crossed with Oma1 E324Q knock-in mice, cytochrome c rescue assay, copper homeostasis measurements, proteomic profiling of insoluble mitochondrial proteins","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution rescue by exogenous cytochrome c, genetic epistasis with OMA1 catalytic mutant, proteomic profiling, multiple orthogonal methods in single study","pmids":["41420107"],"is_preprint":false},{"year":2024,"finding":"CHCHD2 and CHCHD10 interact with ATG8-family proteins (preferentially GABARAPs) and with C1QBP/p32 to form a CHCHD2-CHCHD10-C1QBP-ATG8 complex; through GABARAP binding, CHCHD2 and CHCHD10 undergo autophagic degradation and recruit the ULK1 complex; CHCHD2 and CHCHD10 promote autophagy initiation and reduce protein aggregates.","method":"Co-immunoprecipitation, iPSC-derived CHCHD2 knockout neurons, autophagy flux assays, ULK1 complex recruitment assay, in vivo α-synuclein aggregate reduction","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP defining multiprotein complex, functional autophagy assays, KO neuronal models, single lab","pmids":["42183628"],"is_preprint":false},{"year":2025,"finding":"In mouse tissues, CHCHD2 and CHCHD10 exist exclusively as a high molecular weight complex whose levels are finely tuned; in response to mitochondrial dysfunction, the abundance and size of the CHCHD2-CHCHD10 complex increase, a mechanism conserved across different tissues; loss of CHCHD2 does not abolish CHCHD10 oligomerization but enhances cell vulnerability to mitochondrial stress.","method":"Whole-body Chchd2 knockout mouse, BN-PAGE complex analysis, mitochondrial stress treatments across tissues","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse knockout with BN-PAGE complex analysis, stress-response characterization, single lab","pmids":["41053020"],"is_preprint":false},{"year":2025,"finding":"Nifuroxazide rescues mitochondrial network fragmentation and cristae abnormalities in CHCHD10 S59L/+ patient fibroblasts; the rescue mechanism involves KIF5B-mediated mitochondrial transport enhancement with increased axonal movement and syntaphilin degradation in patient-derived motor neurons.","method":"Drug screen in yeast MICOS mutant strains, patient fibroblast rescue assay, iPSC-derived motor neuron live imaging, syntaphilin quantification","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast screen plus patient cell and iPSC rescue with mechanistic transport readout, single lab","pmids":["39478664"],"is_preprint":false}],"current_model":"CHCHD10 is a nuclear-encoded mitochondrial intermembrane space protein that localizes to cristae junctions as part of the MICOS complex (with mitofilin, CHCHD3, CHCHD6) and forms heterodimers/high-molecular-weight complexes with its paralog CHCHD2; it supports mitochondrial cristae integrity, Complex I and Complex IV (COX) assembly, and efficient oxidative phosphorylation, while also suppressing OMA1 peptidase activity to prevent aberrant OPA1 cleavage and mtISR activation; disease-associated gain-of-function mutations (notably S59L and G58R) cause CHCHD10 to misfold and aggregate, disrupting MICOS/PHB/OPA1-mitofilin complexes, impairing cytochrome c biogenesis, activating the OMA1-DELE1-HRI integrated stress response axis, inducing widespread metabolic rewiring, and promoting TDP-43 aggregation, while haploinsufficiency mutations (R15L, G66V) reduce protein levels and impair Complex I assembly and respiration."},"narrative":{"mechanistic_narrative":"CHCHD10 is a nuclear-encoded mitochondrial intermembrane-space protein, enriched at cristae junctions, that supports cristae architecture and oxidative phosphorylation [PMID:24934289, PMID:26666268]. It is imported via Mia40-dependent disulfide-bond formation through its CHCH domain rather than a canonical N-terminal targeting signal, and the ALS variant Q108P blocks import to cause cytoplasmic mislocalization [PMID:29789341]. Structurally, CHCHD10 is a constituent of the MICOS complex with mitofilin, CHCHD3 and CHCHD6, and forms heterodimers and a ~220 kDa high-molecular-weight complex with its paralog CHCHD2, which exist in vivo essentially exclusively as a finely tuned, stress-responsive HMW assembly [PMID:26666268, PMID:29121267, PMID:30084972, PMID:41053020]. Functionally, CHCHD10 contributes to Complex I assembly and respiration and to cytochrome c oxidase (Complex IV) activity [PMID:29121267, PMID:20888800], with mutant work pinpointing IMS proteostasis and cytochrome c biogenesis (copper-dependent) as early bioenergetic requirements [PMID:41420107]. Together with CHCHD2, CHCHD10 binds and restrains the OMA1 metallopeptidase to prevent aberrant cleavage of L-OPA1, and the two paralogs are partially functionally redundant; loss of both, or mutant aggregation, activates OMA1, triggering OPA1 processing, cristae disruption and the integrated stress response via DELE1 cleavage [PMID:32338760, PMID:35173147, PMID:35700042]. CHCHD10 also stabilizes the SLP2-prohibitin and OPA1-mitofilin complexes [PMID:35656794, PMID:32369233]. Disease-associated mutations act predominantly through gain of toxic function: S59L/S55L and G58R cause CHCHD10 to misfold into amyloid fibrils formed by its disordered N-terminal domain (a structure incompatible with disease mutations but tolerant of CHCHD2 differences, explaining co-aggregation), driving a proteotoxic mitochondrial integrated stress response, metabolic rewiring, and enhanced TDP-43 aggregation, while ablation of CHCHD10 does not reproduce disease pathology [PMID:30877432, PMID:35700042, PMID:35263592, PMID:35787294]. Distinct haploinsufficiency mutations (R15L, G66V) reduce protein levels and impair Complex I assembly and respiration [PMID:29315381, PMID:29121267]. CHCHD10 dysfunction links mitochondrial failure to motor pathology by promoting cytoplasmic TDP-43 accumulation and disrupting PINK1/PARL-dependent mitophagy [PMID:28585542, PMID:33772006, PMID:38132101]. Mutations in CHCHD10 cause FTD/ALS-spectrum disease through these convergent mechanisms [PMID:28585542, PMID:30874923].","teleology":[{"year":2010,"claim":"Established the first functional link between CHCHD10 and the respiratory chain, before its disease relevance was known.","evidence":"siRNA knockdown with Complex IV activity assay in vitro","pmids":["20888800"],"confidence":"Medium","gaps":["No localization or mechanism defining how CHCHD10 supports COX","Single functional readout"]},{"year":2014,"claim":"Resolved where CHCHD10 acts and that a disease mutation has structural consequences, localizing it to the IMS/cristae junctions and showing S59L disrupts the mitochondrial network and cristae.","evidence":"Immunofluorescence, subcellular fractionation, S59L overexpression in HeLa with ultrastructural imaging","pmids":["24934289"],"confidence":"High","gaps":["Overexpression rather than endogenous mutant","Molecular partners undefined"]},{"year":2016,"claim":"Defined CHCHD10's structural context by placing it in the MICOS complex and connecting MICOS disassembly to cristae loss, nucleoid disorganization and altered apoptosis.","evidence":"Reciprocal Co-IP, patient fibroblasts, EM, apoptosis assays","pmids":["26666268"],"confidence":"High","gaps":["Direct vs. indirect MICOS contact not resolved","mtDNA-repair link mechanistically thin"]},{"year":2017,"claim":"Connected mitochondrial CHCHD10 function to the central ALS/FTD proteinopathy by showing loss of function and dominant-negative mutants drive cytoplasmic TDP-43 accumulation.","evidence":"C. elegans complementation, mammalian cells, primary neurons, mouse brains","pmids":["28585542"],"confidence":"High","gaps":["Loss- vs gain-of-function balance left ambiguous across systems","Molecular route from mitochondria to TDP-43 not defined"]},{"year":2018,"claim":"Characterized the CHCHD10-CHCHD2 partnership and the import pathway, showing heterodimer/HMW complex formation, CHCHD2-dependent oligomerization, and Mia40/CHCH-domain-dependent import disrupted by Q108P.","evidence":"Reciprocal Co-IP, BN-PAGE, double-knockout cells, Mia40 KD/OE rescue, truncations, interactome MS","pmids":["29112723","29121267","30084972","29789341"],"confidence":"High","gaps":["Functional significance of HMW complex not yet defined","p32/GC1QR interaction role unclear"]},{"year":2018,"claim":"Distinguished mutation classes mechanistically, defining R15L/G66V as haploinsufficiency reducing protein and impairing Complex I, versus gain-of-toxic-function variants, and proposing a nuclear transcriptional/COX-scaffolding role.","evidence":"Patient cells, zebrafish knockdown, BN-PAGE, COX co-purification, transcriptional reporters","pmids":["29121267","29315381","29540477"],"confidence":"Medium","gaps":["Nuclear CXXC5/ORE role not independently replicated","Reconciliation of loss- vs gain-of-function across variants incomplete"]},{"year":2019,"claim":"Established gain-of-toxic-function in vivo and ordered the pathology, showing knock-in (not knockout) mice aggregate CHCHD10 with CHCHD2, induce mtISR via mTORC1, and target muscle before NMJ and motor neurons.","evidence":"S55L/S59L knock-in mice with knockout comparison, omics, temporal histopathology, iPSC motor neurons","pmids":["30877432","30874923"],"confidence":"High","gaps":["Trigger of aggregation in specific tissues unknown","Link between aggregation and mtISR not yet mechanistic"]},{"year":2020,"claim":"Identified the OMA1-OPA1 axis as the effector pathway, showing CHCHD2/CHCHD10 loss activates OMA1 to cleave L-OPA1, that the paralogs are partially redundant, and that TDP-43 lowers CHCHD10 to disassemble OPA1-mitofilin complexes.","evidence":"Double-knockout and knock-in mice, OPA1 cleavage/OMA1 assays, Co-IP, fusion/respiration assays, FTLD-TDP brains","pmids":["32338760","32369233"],"confidence":"High","gaps":["How CHCHD10 restrains OMA1 mechanistically not shown","Directness of TDP-43 effect on CHCHD10 unclear"]},{"year":2020,"claim":"Extended CHCHD10 function to peripheral tissue physiology, linking its ATP-generating role to AChR clustering at the NMJ.","evidence":"Muscle conditional knockout mice with ATP rescue, AChR clustering and electrophysiology","pmids":["31261376"],"confidence":"Medium","gaps":["Single-lab finding","Relationship to mutant pathology not established"]},{"year":2021,"claim":"Mapped the downstream metabolic and stress consequences, showing R15L Complex I deficiency rewires one-carbon/TCA metabolism and AMPK/mTORC1 and triggers ER and mitochondrial UPR, while S59L chronically activates PINK1 with TDP-43 mitochondrial translocation.","evidence":"Multi-omics in patient cells; Drosophila/HeLa with PINK1 manipulation and TDP-43 translocation inhibitor","pmids":["33749723","33772006"],"confidence":"Medium","gaps":["Causal ordering of metabolic vs stress responses incomplete","PINK1 activation mechanism not yet defined"]},{"year":2022,"claim":"Consolidated the mechanism, demonstrating CHCHD2/CHCHD10 directly suppress OMA1 and bind eIF2alpha to limit mtISR, stabilize the SLP2-prohibitin complex, and that OMA1 acts via DELE1 cleavage to drive the ISR essential for mutant-mouse survival.","evidence":"Co-IP/OMA1 enzymatic assays, G58R and S59L knock-in mice with OMA1 ablation, DELE1 cleavage assay, omics, EM","pmids":["35173147","35656794","35700042"],"confidence":"High","gaps":["Cytosolic eIF2alpha interaction needs independent replication","Stoichiometry of OMA1 suppression unknown"]},{"year":2022,"claim":"Showed proteotoxic mtISR drives metabolic rewiring before bioenergetic failure and defined non-disease metabolic roles in adipocyte browning and lipolysis.","evidence":"S55L knock-in heart metabolomics/flux with temporal staging; adipocyte-specific KO with ATGL rescue; KO cold-challenge; in vivo TDP-43 Co-IP","pmids":["35263592","35709007","35362877"],"confidence":"High","gaps":["How aggregation initiates metabolic rewiring unresolved","Tissue specificity of browning role not generalized"]},{"year":2022,"claim":"Demonstrated reconstituted aggregation behavior, showing S59L promotes self- and TDP-43 aggregation in isolated mitochondria/cell-free systems and that WT CHCHD10 suppresses TDP-43 aggregate growth.","evidence":"Cell-free aggregation, isolated mitochondria, filter trap, AFM, transgenic mice, human brain","pmids":["35787294"],"confidence":"Medium","gaps":["In vitro relevance to in vivo seeding uncertain","Single lab"]},{"year":2023,"claim":"Linked CHCHD10 to mitophagy quality control, showing WT suppresses PARL to stabilize PINK1 and support Parkin recruitment/mitophagy, while mutants increase PARL activity, impair mitophagy and promote TDP-43 aggregation.","evidence":"Co-IP CHCHD10-PARL, PARL activity and mitophagy flux assays, Parkin recruitment, in vivo and human FTD brain","pmids":["38132101"],"confidence":"Medium","gaps":["Directness of PARL regulation needs confirmation","Reconciliation with PINK1-activation finding from 2021"]},{"year":2024,"claim":"Provided structural basis for aggregation, resolving CHCHD10 N-terminal amyloid fibrils by cryoEM and explaining why disease mutations destabilize the fold while CHCHD2 differences are tolerated, rationalizing co-aggregation.","evidence":"CryoEM structure of N-terminal-domain amyloid fibrils (preprint)","pmids":[],"confidence":"High","gaps":["Preprint, not peer reviewed","Fibril relevance to in vivo aggregates not established"]},{"year":2024,"claim":"Identified a CHCHD2-CHCHD10-C1QBP-ATG8 complex through which the paralogs promote autophagy initiation, recruit ULK1, and reduce protein aggregates.","evidence":"Reciprocal Co-IP, iPSC CHCHD2-KO neurons, autophagy flux, ULK1 recruitment, in vivo aggregate reduction","pmids":["42183628"],"confidence":"Medium","gaps":["Single lab","How an IMS protein engages cytosolic ATG8 machinery unclear"]},{"year":2025,"claim":"Dissected the earliest pathogenic defect and uncoupled stress from bioenergetics, showing impaired copper homeostasis and cytochrome c biogenesis is rescuable by exogenous cytochrome c, while OMA1 catalytic inactivation delays cardiomyopathy without rescuing insolubility, cristae or OXPHOS defects.","evidence":"S55L knock-in crossed with Oma1 E324Q mice, cytochrome c rescue, copper measurements, insoluble-proteome profiling","pmids":["41420107"],"confidence":"High","gaps":["Mechanism linking IMS proteostasis to copper handling unresolved","Therapeutic implications of mtISR/bioenergetics uncoupling untested"]},{"year":2025,"claim":"Characterized the native CHCHD2-CHCHD10 complex as an essentially obligate, stress-tunable HMW assembly conserved across tissues, with CHCHD2 loss sensitizing cells to mitochondrial stress.","evidence":"Whole-body Chchd2 KO mouse, BN-PAGE, cross-tissue stress treatments","pmids":["41053020"],"confidence":"Medium","gaps":["Subunit stoichiometry and additional components undefined","Functional output of complex enlargement unclear"]},{"year":null,"claim":"How the disordered N-terminal aggregation seed mechanistically couples to specific downstream effectors (OMA1, PARL/PINK1, TDP-43, copper/cytochrome c biogenesis) to determine tissue-selective vulnerability remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of which effector arm is primary in each affected tissue","No therapeutic target validated in patients","Order of aggregation, mtISR, and bioenergetic failure not fully resolved in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,11,17]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1,10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,18]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,18,24]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[7,11,9]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,1,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,20]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[17,28]}],"complexes":["MICOS complex","CHCHD2-CHCHD10 high-molecular-weight complex","SLP2-prohibitin (PHB) complex","CHCHD2-CHCHD10-C1QBP-ATG8 complex"],"partners":["CHCHD2","OMA1","PARL","C1QBP","SLP2","TDP-43","CXXC5","GABARAP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WYQ3","full_name":"Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial","aliases":["Protein N27C7-4"],"length_aa":142,"mass_kda":14.1,"function":"May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure","subcellular_location":"Mitochondrion intermembrane space","url":"https://www.uniprot.org/uniprotkb/Q8WYQ3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHCHD10","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHCHD10","total_profiled":1310},"omim":[{"mim_id":"616209","title":"MYOPATHY, ISOLATED MITOCHONDRIAL, AUTOSOMAL DOMINANT; IMMD","url":"https://www.omim.org/entry/616209"},{"mim_id":"616208","title":"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 9; FTDALS9","url":"https://www.omim.org/entry/616208"},{"mim_id":"615911","title":"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 2; FTDALS2","url":"https://www.omim.org/entry/615911"},{"mim_id":"615903","title":"COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 10; CHCHD10","url":"https://www.omim.org/entry/615903"},{"mim_id":"615048","title":"SPINAL MUSCULAR ATROPHY, JOKELA TYPE; SMAJ","url":"https://www.omim.org/entry/615048"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":1596.3},{"tissue":"skeletal muscle","ntpm":1222.7}],"url":"https://www.proteinatlas.org/search/CHCHD10"},"hgnc":{"alias_symbol":["N27C7-4","MIX17A"],"prev_symbol":["C22orf16"]},"alphafold":{"accession":"Q8WYQ3","domains":[{"cath_id":"1.10.287","chopping":"98-142","consensus_level":"medium","plddt":82.4367,"start":98,"end":142}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WYQ3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WYQ3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WYQ3-F1-predicted_aligned_error_v6.png","plddt_mean":61.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHCHD10","jax_strain_url":"https://www.jax.org/strain/search?query=CHCHD10"},"sequence":{"accession":"Q8WYQ3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WYQ3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WYQ3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WYQ3"}},"corpus_meta":[{"pmid":"24934289","id":"PMC_24934289","title":"A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24934289","citation_count":408,"is_preprint":false},{"pmid":"26666268","id":"PMC_26666268","title":"CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis.","date":"2016","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26666268","citation_count":160,"is_preprint":false},{"pmid":"25155093","id":"PMC_25155093","title":"Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25155093","citation_count":113,"is_preprint":false},{"pmid":"25193783","id":"PMC_25193783","title":"Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy.","date":"2014","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25193783","citation_count":100,"is_preprint":false},{"pmid":"28585542","id":"PMC_28585542","title":"Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28585542","citation_count":100,"is_preprint":false},{"pmid":"25428574","id":"PMC_25428574","title":"Late onset spinal motor neuronopathy is caused by mutation in CHCHD10.","date":"2014","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25428574","citation_count":94,"is_preprint":false},{"pmid":"29112723","id":"PMC_29112723","title":"In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29112723","citation_count":89,"is_preprint":false},{"pmid":"30877432","id":"PMC_30877432","title":"ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/30877432","citation_count":88,"is_preprint":false},{"pmid":"30874923","id":"PMC_30874923","title":"Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10S59L/+ mouse.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/30874923","citation_count":79,"is_preprint":false},{"pmid":"27066538","id":"PMC_27066538","title":"CHCHD10 variant p.(Gly66Val) causes axonal Charcot-Marie-Tooth disease.","date":"2015","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27066538","citation_count":72,"is_preprint":false},{"pmid":"29121267","id":"PMC_29121267","title":"Loss of CHCHD10-CHCHD2 complexes required for respiration underlies the pathogenicity of a CHCHD10 mutation in ALS.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29121267","citation_count":65,"is_preprint":false},{"pmid":"32338760","id":"PMC_32338760","title":"Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phenocopying patient mutations.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32338760","citation_count":64,"is_preprint":false},{"pmid":"35173147","id":"PMC_35173147","title":"CHCHD2 and CHCHD10 regulate mitochondrial dynamics and integrated stress response.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35173147","citation_count":63,"is_preprint":false},{"pmid":"28069311","id":"PMC_28069311","title":"Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28069311","citation_count":60,"is_preprint":false},{"pmid":"30496485","id":"PMC_30496485","title":"PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30496485","citation_count":58,"is_preprint":false},{"pmid":"35700042","id":"PMC_35700042","title":"OMA1 mediates local and global stress responses against protein misfolding in CHCHD10 mitochondrial myopathy.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35700042","citation_count":57,"is_preprint":false},{"pmid":"29540477","id":"PMC_29540477","title":"The cellular stress proteins CHCHD10 and MNRR1 (CHCHD2): Partners in mitochondrial and nuclear function and dysfunction.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29540477","citation_count":57,"is_preprint":false},{"pmid":"30084972","id":"PMC_30084972","title":"CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30084972","citation_count":54,"is_preprint":false},{"pmid":"33749723","id":"PMC_33749723","title":"Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33749723","citation_count":54,"is_preprint":false},{"pmid":"30092269","id":"PMC_30092269","title":"Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30092269","citation_count":54,"is_preprint":false},{"pmid":"30791515","id":"PMC_30791515","title":"Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30791515","citation_count":47,"is_preprint":false},{"pmid":"29789341","id":"PMC_29789341","title":"A novel CHCHD10 mutation implicates a Mia40-dependent mitochondrial import deficit in ALS.","date":"2018","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29789341","citation_count":45,"is_preprint":false},{"pmid":"31261376","id":"PMC_31261376","title":"Loss of mitochondrial protein CHCHD10 in skeletal muscle causes neuromuscular junction impairment.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31261376","citation_count":37,"is_preprint":false},{"pmid":"32369233","id":"PMC_32369233","title":"CHCHD10-regulated OPA1-mitofilin complex mediates TDP-43-induced mitochondrial phenotypes associated with frontotemporal dementia.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32369233","citation_count":36,"is_preprint":false},{"pmid":"20888800","id":"PMC_20888800","title":"Functional annotation of heart enriched mitochondrial genes GBAS and CHCHD10 through guilt by association.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20888800","citation_count":36,"is_preprint":false},{"pmid":"29315381","id":"PMC_29315381","title":"CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29315381","citation_count":33,"is_preprint":false},{"pmid":"28462717","id":"PMC_28462717","title":"Genetic Features of MAPT, GRN, C9orf72 and CHCHD10 Gene Mutations in Chinese Patients with Frontotemporal Dementia.","date":"2017","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/28462717","citation_count":31,"is_preprint":false},{"pmid":"32437855","id":"PMC_32437855","title":"ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32437855","citation_count":30,"is_preprint":false},{"pmid":"35263592","id":"PMC_35263592","title":"Mutant CHCHD10 causes an extensive metabolic rewiring that precedes OXPHOS dysfunction in a murine model of mitochondrial cardiomyopathy.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35263592","citation_count":26,"is_preprint":false},{"pmid":"30014597","id":"PMC_30014597","title":"CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence?","date":"2018","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30014597","citation_count":25,"is_preprint":false},{"pmid":"35656794","id":"PMC_35656794","title":"CHCHD10 and SLP2 control the stability of the PHB complex: a key factor for motor neuron viability.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35656794","citation_count":25,"is_preprint":false},{"pmid":"31526091","id":"PMC_31526091","title":"Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications.","date":"2019","source":"The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31526091","citation_count":24,"is_preprint":false},{"pmid":"35787294","id":"PMC_35787294","title":"Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35787294","citation_count":24,"is_preprint":false},{"pmid":"32042922","id":"PMC_32042922","title":"Neuropathologic description of CHCHD10 mutated amyotrophic lateral sclerosis.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32042922","citation_count":23,"is_preprint":false},{"pmid":"26224640","id":"PMC_26224640","title":"Intrafamilial clinical variability in individuals carrying the CHCHD10 mutation Gly66Val.","date":"2015","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/26224640","citation_count":23,"is_preprint":false},{"pmid":"33772006","id":"PMC_33772006","title":"TDP-43 and PINK1 mediate CHCHD10S59L mutation-induced defects in Drosophila and in vitro.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33772006","citation_count":22,"is_preprint":false},{"pmid":"27056076","id":"PMC_27056076","title":"Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27056076","citation_count":21,"is_preprint":false},{"pmid":"27578015","id":"PMC_27578015","title":"Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27578015","citation_count":21,"is_preprint":false},{"pmid":"35709007","id":"PMC_35709007","title":"CHCHD10 Modulates Thermogenesis of Adipocytes by Regulating Lipolysis.","date":"2022","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/35709007","citation_count":20,"is_preprint":false},{"pmid":"37021679","id":"PMC_37021679","title":"CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.","date":"2023","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/37021679","citation_count":19,"is_preprint":false},{"pmid":"30530185","id":"PMC_30530185","title":"CHCHD10 is involved in the development of Parkinson's disease caused by CHCHD2 loss-of-function mutation p.T61I.","date":"2018","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/30530185","citation_count":19,"is_preprint":false},{"pmid":"35349255","id":"PMC_35349255","title":"Structures of the Wild-Type and S59L Mutant CHCHD10 Proteins Important in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia.","date":"2022","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35349255","citation_count":18,"is_preprint":false},{"pmid":"36061599","id":"PMC_36061599","title":"CHCHD2 and CHCHD10: Future therapeutic targets in cognitive disorder and motor neuron disorder.","date":"2022","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36061599","citation_count":13,"is_preprint":false},{"pmid":"27095681","id":"PMC_27095681","title":"Genetic analysis of CHCHD10 in French familial amyotrophic lateral sclerosis patients.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/27095681","citation_count":13,"is_preprint":false},{"pmid":"36799027","id":"PMC_36799027","title":"Loss of mitochondrial Chchd10 or Chchd2 in zebrafish leads to an ALS-like phenotype and Complex I deficiency independent of the mitochondrial integrated stress response.","date":"2023","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36799027","citation_count":12,"is_preprint":false},{"pmid":"33659869","id":"PMC_33659869","title":"Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33659869","citation_count":12,"is_preprint":false},{"pmid":"28318595","id":"PMC_28318595","title":"CHCHD10 mutations in patients with amyotrophic lateral sclerosis in Mainland China.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28318595","citation_count":12,"is_preprint":false},{"pmid":"35362877","id":"PMC_35362877","title":"Chchd10 is dispensable for myogenesis but critical for adipose browning.","date":"2022","source":"Cell regeneration (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35362877","citation_count":11,"is_preprint":false},{"pmid":"38132101","id":"PMC_38132101","title":"Disruption of Mitophagy Flux through the PARL-PINK1 Pathway by CHCHD10 Mutations or CHCHD10 Depletion.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38132101","citation_count":10,"is_preprint":false},{"pmid":"38724625","id":"PMC_38724625","title":"High fat diet ameliorates mitochondrial cardiomyopathy in CHCHD10 mutant mice.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38724625","citation_count":9,"is_preprint":false},{"pmid":"31690696","id":"PMC_31690696","title":"Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice.","date":"2019","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31690696","citation_count":9,"is_preprint":false},{"pmid":"29519717","id":"PMC_29519717","title":"Mutation analysis of CHCHD2 and CHCHD10 in Italian patients with mitochondrial myopathy.","date":"2018","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/29519717","citation_count":9,"is_preprint":false},{"pmid":"27077676","id":"PMC_27077676","title":"CHCHD10 is not a frequent causative gene in Chinese ALS patients.","date":"2016","source":"Amyotrophic lateral sclerosis & frontotemporal degeneration","url":"https://pubmed.ncbi.nlm.nih.gov/27077676","citation_count":9,"is_preprint":false},{"pmid":"38583639","id":"PMC_38583639","title":"CHCHD10S59L/+ mouse model: Behavioral and neuropathological features of frontotemporal dementia.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38583639","citation_count":8,"is_preprint":false},{"pmid":"35250809","id":"PMC_35250809","title":"Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35250809","citation_count":8,"is_preprint":false},{"pmid":"28108040","id":"PMC_28108040","title":"Genetic analysis of CHCHD2 and CHCHD10 in Italian patients with Parkinson's disease.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28108040","citation_count":7,"is_preprint":false},{"pmid":"40400037","id":"PMC_40400037","title":"Dose-dependent CHCHD10 dysregulation dictates motor neuron disease severity and alters creatine metabolism.","date":"2025","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/40400037","citation_count":5,"is_preprint":false},{"pmid":"38453793","id":"PMC_38453793","title":"Loss of CHCHD2 Stability Coordinates with C1QBP/CHCHD2/CHCHD10 Complex Impairment to Mediate PD-Linked Mitochondrial Dysfunction.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38453793","citation_count":5,"is_preprint":false},{"pmid":"38211361","id":"PMC_38211361","title":"NDV inhibited IFN-β secretion through impeding CHCHD10-mediated mitochondrial fusion to promote viral proliferation.","date":"2023","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/38211361","citation_count":5,"is_preprint":false},{"pmid":"37767023","id":"PMC_37767023","title":"The identification of high-performing antibodies for Coiled-coil-helix-coiled-coil-helix domain containing protein 10 (CHCHD10) for use in Western Blot, immunoprecipitation and immunofluorescence.","date":"2023","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/37767023","citation_count":5,"is_preprint":false},{"pmid":"36625206","id":"PMC_36625206","title":"Effects of the Jokela type of spinal muscular atrophy-related G66V mutation on the structural ensemble characteristics of CHCHD10.","date":"2023","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/36625206","citation_count":5,"is_preprint":false},{"pmid":"37815936","id":"PMC_37815936","title":"CHCHD10 mutations induce tissue-specific mitochondrial DNA deletions with a distinct signature.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37815936","citation_count":4,"is_preprint":false},{"pmid":"39260590","id":"PMC_39260590","title":"CHCHD10P80L knock-in zebrafish display a mild ALS-like phenotype.","date":"2024","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39260590","citation_count":3,"is_preprint":false},{"pmid":"39985288","id":"PMC_39985288","title":"Chchd10: A Novel Metabolic Sensor Modulating Adipose Tissue Homeostasis.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39985288","citation_count":3,"is_preprint":false},{"pmid":"37194187","id":"PMC_37194187","title":"Frontotemporal Dementia-Related V57E Mutation Impairs Mitochondrial Function and Alters the Structural Properties of CHCHD10.","date":"2023","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37194187","citation_count":3,"is_preprint":false},{"pmid":"41420107","id":"PMC_41420107","title":"Mutant CHCHD10 disrupts cytochrome c oxidation and activates mitochondrial retrograde signaling.","date":"2025","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41420107","citation_count":2,"is_preprint":false},{"pmid":"37349880","id":"PMC_37349880","title":"The impacts of the mitochondrial myopathy-associated G58R mutation on the dynamic structural properties of CHCHD10.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37349880","citation_count":2,"is_preprint":false},{"pmid":"36865125","id":"PMC_36865125","title":"High fat diet ameliorates mitochondrial cardiomyopathy in CHCHD10 mutant mice.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36865125","citation_count":2,"is_preprint":false},{"pmid":"40170896","id":"PMC_40170896","title":"Combined impact of CHCHD10 p.Gly66Val and three other variants suggests oligogenic contributions to ALS.","date":"2025","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40170896","citation_count":2,"is_preprint":false},{"pmid":"39444183","id":"PMC_39444183","title":"Effects of the Amyotrophic Lateral Sclerosis-related Q108P Mutation on the Structural Ensemble Characteristics of CHCHD10.","date":"2025","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/39444183","citation_count":2,"is_preprint":false},{"pmid":"41053020","id":"PMC_41053020","title":"The CHCHD2-CHCHD10 protein complex is modulated by mitochondrial dysfunction and alters lipid homeostasis in the mouse brain.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41053020","citation_count":1,"is_preprint":false},{"pmid":"38244394","id":"PMC_38244394","title":"Mitochondrial protein CHCHD10 inhibits NDV replication and reduces pathological changes.","date":"2024","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/38244394","citation_count":1,"is_preprint":false},{"pmid":"41040684","id":"PMC_41040684","title":"Clinical, neuropathological, and biochemical characterization of ALS in a large CHCHD10 R15L family.","date":"2025","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41040684","citation_count":1,"is_preprint":false},{"pmid":"39478664","id":"PMC_39478664","title":"Nifuroxazide rescues the deleterious effects due to CHCHD10-associated MICOS defects in disease models.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39478664","citation_count":1,"is_preprint":false},{"pmid":"41303337","id":"PMC_41303337","title":"SLP2/PHB Aggregates in ALS Mouse Models and Patients: Implications Beyond CHCHD10-Associated Motor Neuron Disease.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41303337","citation_count":1,"is_preprint":false},{"pmid":"41509469","id":"PMC_41509469","title":"A mouse model of CHCHD10 p.R15L familial ALS presents mild, age-related motor neuron degeneration without protein instability or mitochondrial dysfunction.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41509469","citation_count":1,"is_preprint":false},{"pmid":"40490178","id":"PMC_40490178","title":"Impacts of pathogenic mutations on the structures of the CHCHD10 monomer: An AlphaFold3 study linked to the generation of conformational ensembles.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40490178","citation_count":1,"is_preprint":false},{"pmid":"40452868","id":"PMC_40452868","title":"har-1/CHCHD10 mutations induce neurodegeneration and mitochondrial fragmentation in Caenorhabditis elegans.","date":"2025","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/40452868","citation_count":0,"is_preprint":false},{"pmid":"32651855","id":"PMC_32651855","title":"Meta-analysis of the association between CHCHD10 Pro34Ser variant and the risk of amyotrophic lateral sclerosis.","date":"2020","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/32651855","citation_count":0,"is_preprint":false},{"pmid":"38895204","id":"PMC_38895204","title":"FDA-approved PDE4 inhibitors reduce the dominant toxicity of ALS-FTD-associated CHCHD10 .","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38895204","citation_count":0,"is_preprint":false},{"pmid":"42183628","id":"PMC_42183628","title":"CHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs.","date":"2026","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/42183628","citation_count":0,"is_preprint":false},{"pmid":"41911331","id":"PMC_41911331","title":"Clinical and biochemical characterization of amyotrophic lateral sclerosis in a CHCHD10 R15L family.","date":"2026","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41911331","citation_count":0,"is_preprint":false},{"pmid":"41633268","id":"PMC_41633268","title":"A FEN1-EDCR dual-amplification strategy for ultrasensitive detection of CHCHD10 c.176C>T mutation.","date":"2026","source":"Biosensors & bioelectronics","url":"https://pubmed.ncbi.nlm.nih.gov/41633268","citation_count":0,"is_preprint":false},{"pmid":"41732281","id":"PMC_41732281","title":"FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10S59L in Drosophila and human cells.","date":"2026","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41732281","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.18.668848","title":"Mutant CHCHD10 disrupts cytochrome  <i>c</i>  oxidation and activates mitochondrial retrograde signaling in a model of cardiomyopathy","date":"2025-08-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.668848","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.13.637962","title":"Investigation of mitochondrial phenotypes in motor neurons derived by direct conversion of fibroblasts from familial ALS subjects","date":"2025-02-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.13.637962","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.18.604174","title":"Amyloid fibril structures link CHCHD10 and CHCHD2 to neurodegeneration","date":"2024-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.18.604174","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.22.24309342","title":"A Mendelian randomization study identifies the causal association between plasma mitochondrial CHCHD proteins and polycystic ovary syndrome","date":"2024-06-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.22.24309342","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44951,"output_tokens":8105,"usd":0.128214,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17907,"output_tokens":6052,"usd":0.120417,"stage2_stop_reason":"end_turn"},"total_usd":0.248631,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"CHCHD10 is a mitochondrial protein localized to the intermembrane space and enriched at cristae junctions; overexpression of the S59L mutant allele in HeLa cells causes fragmentation of the mitochondrial network and major ultrastructural abnormalities including loss, disorganization and dilatation of cristae.\",\n      \"method\": \"Immunofluorescence, subcellular fractionation, overexpression in HeLa cells with mitochondrial network imaging\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiment with functional consequence, replicated across multiple subsequent studies; original discovery paper with multiple orthogonal methods\",\n      \"pmids\": [\"24934289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CHCHD10 resides within the MICOS (mitochondrial contact site and cristae organizing system) complex together with mitofilin, CHCHD3, and CHCHD6; CHCHD10 mutations lead to MICOS complex disassembly, loss of mitochondrial cristae, decreased nucleoid number and disorganization, impaired mtDNA repair after oxidative stress, and inhibition of apoptosis by preventing cytochrome c release.\",\n      \"method\": \"Co-immunoprecipitation, patient fibroblast analysis, immunofluorescence, electron microscopy, apoptosis assays\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying MICOS complex membership, multiple orthogonal functional assays, replicated in subsequent studies\",\n      \"pmids\": [\"26666268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHCHD10 localizes to the mitochondrial intermembrane space where it physically interacts with CHCHD2 and with p32/GC1QR; CHCHD10 and CHCHD2 have short half-lives suggesting regulatory rather than structural functions; CHCHD10 knockdown causes accumulation of excessive intramitochondrial iron but no bioenergetic defects; cells expressing S59L or R15L mutant CHCHD10 (but not WT) show impaired mitochondrial energy metabolism, supporting a gain-of-toxic-function mechanism.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry interactome, CHCHD10 knockdown cell lines, metabolic assays, mouse tissue expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus MS interactome, KD with defined cellular phenotype, multiple orthogonal methods in single study\",\n      \"pmids\": [\"29112723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The p.R15L CHCHD10 variant in ALS patient fibroblasts destabilizes the protein, causing defective assembly of Complex I, impaired cellular respiration, mitochondrial hyperfusion, and increased CHCHD2 levels; CHCHD10 and CHCHD2 co-immunoprecipitate quantitatively and co-migrate in a ~220 kDa high-molecular-weight complex by BN-PAGE, which is absent in patient cells.\",\n      \"method\": \"Blue native PAGE, reciprocal co-immunoprecipitation, oxygen consumption assays, patient fibroblasts\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, BN-PAGE complex analysis, patient cells with functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"29121267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHCHD10 and CHCHD2 are similarly distributed throughout mitochondrial cristae and form heterodimers; CHCHD2 is preferentially stabilized by loss of mitochondrial membrane potential, and CHCHD10 oligomerization depends on CHCHD2 expression; disease-causing mutations in both proteins still readily form heterodimers.\",\n      \"method\": \"CHCHD2/CHCHD10 double knockout cell lines, co-immunoprecipitation, immunofluorescence, mitochondrial stress treatments\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout cell lines with reciprocal Co-IP, multiple orthogonal methods including stress-response assays\",\n      \"pmids\": [\"30084972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHCHD10 mitochondrial import is mediated by the CHCH domain rather than the proposed N-terminal mitochondrial targeting signal; mitochondrial import of CHCHD10 depends on Mia40, which introduces disulfide bonds into CHCH domain proteins; the ALS-associated Q108P mutation nearly completely blocks mitochondrial import, causing diffuse cytoplasmic localization; overexpression of Mia40 rescues mitochondrial import of CHCHD10 Q108P by enhancing disulfide-bond formation.\",\n      \"method\": \"Truncation experiments, Mia40 knockdown and overexpression, subcellular fractionation, immunofluorescence\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (truncation analysis, KD/OE rescue), defined mechanistic finding about import pathway\",\n      \"pmids\": [\"29789341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHCHD10 co-purifies with cytochrome c oxidase (COX) and up-regulates COX activity by serving as a scaffolding protein required for MNRR1 (CHCHD2) phosphorylation mediated by ABL2; in the nucleus, CHCHD10 down-regulates expression of genes with oxygen-responsive elements (ORE) by interacting with and augmenting the transcriptional repressor CXXC5; disease variants G66V and P80L show faulty interactions with MNRR1 and COX, reducing respiration and increasing ROS, and abrogate transcriptional repression.\",\n      \"method\": \"Co-purification with COX, nuclear fractionation, transcriptional reporter assays, co-immunoprecipitation with CXXC5, respiration and ROS assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-purification and nuclear interaction data from single lab; multiple methods but not independently replicated\",\n      \"pmids\": [\"29540477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CHCHD10 S55L (equivalent to human S59L) knock-in mice accumulate CHCHD10 in aggregates together with paralog CHCHD2 specifically in affected tissues, leading to aberrant organelle morphology; these aggregates induce a potent mitochondrial integrated stress response (mtISR) through mTORC1 activation with elevation of stress-induced transcription factors, secretion of myokines, upregulated serine and one-carbon metabolism, and downregulation of respiratory chain enzymes; CHCHD10 ablation does not induce disease pathology or activate mtISR, establishing a gain-of-toxic-function mechanism.\",\n      \"method\": \"Knock-in mouse model, immunofluorescence/immunohistochemistry, proteomic and transcriptomic analyses, metabolic assays, knockout comparison\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in and knockout mouse models compared, multiple omics approaches, defined cellular phenotype with pathway placement\",\n      \"pmids\": [\"30877432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of both CHCHD2 and CHCHD10 activates the OMA1 metallopeptidase, which cleaves long-form OPA1 (L-OPA1), causing disrupted mitochondrial cristae; OMA1 activation similarly occurs in affected tissues of mutant CHCHD10 knock-in mice; using OMA1 activation as a functional assay, CHCHD2 and CHCHD10 are found to be partially functionally redundant.\",\n      \"method\": \"CHCHD2/CHCHD10 double knockout mice, knock-in mice, OPA1 cleavage assays, OMA1 activity assays, electron microscopy\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double knockout and knock-in mouse models, mechanistic pathway identified (OMA1-OPA1 axis), multiple orthogonal methods\",\n      \"pmids\": [\"32338760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In physiological conditions, CHCHD2 and CHCHD10 interact with OMA1 and suppress its enzyme activity, restraining initiation of the mitochondrial integrated stress response (mtISR) and suppressing OPA1 processing for mitochondrial fusion; during mitochondrial stress (CCCP treatment), CHCHD2 and CHCHD10 translocate to the cytosol and interact with eIF2α, attenuating mtISR overactivation by suppressing eIF2α phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation with OMA1, OMA1 enzymatic assay, subcellular fractionation under stress, eIF2α phosphorylation assays, knockdown experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and functional enzymatic assay from single lab; translocation experiment adds orthogonal evidence but not independently replicated\",\n      \"pmids\": [\"35173147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHCHD10 interacts with Stomatin-Like Protein 2 (SLP2) and participates in stability of the prohibitin (PHB) complex in the inner mitochondrial membrane; the S59L mutation causes SLP2 and prohibitin to form aggregates in patient fibroblasts and in vivo in spinal motor neurons; PHB complex destabilization activates the OMA1 cascade with OPA1 processing leading to mitochondrial fragmentation and abnormal cristae morphogenesis.\",\n      \"method\": \"Co-immunoprecipitation, patient fibroblasts, CHCHD10S59L/+ knock-in mice, immunohistochemistry, electron microscopy\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus knock-in mouse model with in vivo validation, multiple orthogonal methods from single lab\",\n      \"pmids\": [\"35656794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OMA1-mediated stress response is critical for survival of CHCHD10 G58R knock-in mice; mutant CHCHD10 aggregates apply toxic protein stress to the inner mitochondrial membrane; OMA1 acts both locally (causing mitochondrial fragmentation) and signals outside mitochondria by cleaving DELE1 to activate the integrated stress response (ISR); an isoform switch in terminal electron transport chain complex is also identified as part of this response.\",\n      \"method\": \"CHCHD10 G58R knock-in mouse model, genetic ablation of OMA1, DELE1 cleavage assay, transcriptomic and proteomic analysis, electron microscopy\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knock-in model with OMA1 genetic ablation as epistasis test, DELE1 cleavage mechanistically demonstrated, multiple orthogonal methods\",\n      \"pmids\": [\"35700042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss of function of endogenous CHCHD10 impairs mitochondrial and synaptic integrity and promotes cytoplasmic TDP-43 accumulation; FTD/ALS-associated mutations R15L and S59L exhibit loss-of-function phenotypes in C. elegans genetic complementation assays and dominant negative activities in mammalian systems, causing mitochondrial/synaptic damage and cytoplasmic TDP-43 accumulation.\",\n      \"method\": \"C. elegans genetic complementation, mammalian cell lines, primary neurons, mouse brains; loss-of-function and mutant overexpression with TDP-43 localization readouts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in C. elegans, multiple model systems (worm, mammalian cells, neurons, mouse), multiple orthogonal readouts\",\n      \"pmids\": [\"28585542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CHCHD10 knockdown causes disassembly of OPA1-mitofilin complexes in brain; TDP-43 overexpression reduces CHCHD10 levels and promotes OPA1-mitofilin complex disassembly via CHCHD10, impairing mitochondrial fusion and respiration; wild-type CHCHD10 rescues TDP-43-induced OPA1-mitofilin complex disassembly and mitochondrial defects.\",\n      \"method\": \"CHCHD10 knockdown, TDP-43 overexpression, co-immunoprecipitation of OPA1-mitofilin complexes, mitochondrial fusion assays, respiration assays, transgenic mice, FTLD-TDP patient brains\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue experiment, multiple model systems, single lab\",\n      \"pmids\": [\"32369233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CHCHD10 is required for ATP production in skeletal muscle, which in turn facilitates acetylcholine receptor (AChR) expression and promotes agrin-induced AChR clustering at neuromuscular junctions; ATP addition rescues the reduction of AChR clusters in CHCHD10-ablated muscles.\",\n      \"method\": \"Muscle conditional knockout mice, ATP rescue experiment, AChR clustering assay, electrophysiology\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific rescue by ATP, mechanistic pathway defined, single lab\",\n      \"pmids\": [\"31261376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The CHCHD10 R15L variant causes a complex I deficiency that increases the NADH/NAD+ ratio, diminishes TCA cycle activity, reorganizes one-carbon metabolism, raises AMP/ATP ratio leading to AMPK phosphorylation and mTORC1 inhibition; these metabolic changes activate the UPR in the ER through IRE1/XBP1 and the mitochondrial UPR via ATF4/ATF5 upregulation.\",\n      \"method\": \"Multi-omics (transcriptomics, metabolomics, proteomics) in patient cells under energetic stress\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omics integration with functional pathway mapping, single lab, patient cells\",\n      \"pmids\": [\"33749723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CHCHD10 S59L mutation in Drosophila and HeLa cells increases TDP-43 insolubility and mitochondrial translocation; blocking TDP-43 mitochondrial translocation with a peptide inhibitor reduces CHCHD10 S59L-mediated toxicity; CHCHD10 S59L also chronically activates the PINK1 pathway, and genetic/pharmacological modulation of PINK1 rescues CHCHD10 S59L-induced phenotypes.\",\n      \"method\": \"Drosophila model, HeLa cell model, peptide inhibitor of TDP-43 translocation, PINK1 genetic and pharmacological manipulation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple model systems (Drosophila and human cells), genetic epistasis with PINK1, peptide inhibitor rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"33772006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CHCHD10 mutations (R15L and S59L) reduce PINK1 levels by increasing PARL protease activity, whereas wild-type CHCHD10 suppresses PARL activity through direct interaction, thereby promoting PINK1 stability and mitophagy flux; CHCHD10 mutations impair mitochondrial Parkin recruitment and mitophagy flux, and impaired mitophagy promotes TDP-43 aggregation.\",\n      \"method\": \"In vivo and in vitro models, PARL activity assays, co-immunoprecipitation of CHCHD10-PARL, mitophagy flux assays, Parkin recruitment assays, human FTD brain tissue\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP defining CHCHD10-PARL interaction, PARL activity assay, mitophagy functional readout, single lab with in vivo and human tissue validation\",\n      \"pmids\": [\"38132101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CHCHD10 plays a role in complex IV (cytochrome c oxidase) activity, confirmed by gene knockdown in vitro.\",\n      \"method\": \"siRNA knockdown, complex IV activity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single functional assay with knockdown, single lab, but later replicated by other groups\",\n      \"pmids\": [\"20888800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The p.R15L and p.G66V CHCHD10 mutations cause haploinsufficiency: CHCHD10 protein levels are reduced to ~50% in patient cells (p.R15L at the mRNA level; p.G66V through altered secondary structure and rapid protein degradation); knockdown of CHCHD10 in zebrafish to ~50% causes motoneuron pathology, abnormal myofibrillar structure and motility deficits in vivo.\",\n      \"method\": \"Patient fibroblast protein/mRNA quantification, secondary structure analysis, zebrafish knockdown model with behavioral and histological readouts\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient cell biochemistry combined with zebrafish in vivo model, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"29315381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CHCHD10 S59L/+ knock-in mice develop OXPHOS deficiency in muscle at 3 months, prior to neuromuscular junction fragmentation and motor neuron loss, establishing that the pathological effects of the mutation target muscle before NMJ and motor neurons; CHCHD10 is highly expressed at the NMJ postsynaptic part and S59L mutation causes abnormal CHCHD10 expression at motor end plates.\",\n      \"method\": \"CHCHD10 S59L/+ knock-in mice, temporal histopathological analysis, OXPHOS enzyme histochemistry, motor neuron counting, NMJ morphology assessment, iPSC-derived motor neurons\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse model with temporal dissection of pathology, multiple cell/tissue types, epistatic ordering of pathological events\",\n      \"pmids\": [\"30874923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CHCHD2 T61I mutation causes increased interaction with CHCHD10 and reduced CHCHD10 protein levels; mitochondrial ultrastructural alterations in CHCHD2 T61I patient fibroblasts are similar to those caused by CHCHD10 mutations, implicating CHCHD10 in CHCHD2-related Parkinson's disease pathogenesis.\",\n      \"method\": \"Co-immunoprecipitation in patient fibroblasts, Western blot quantification, electron microscopy\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP in patient cells plus ultrastructural phenotyping, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30530185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHCHD10 deficiency leads to disorganization of mitochondrial cristae, impairment of OXPHOS complex assembly, inhibition of ATP generation, and downregulation of lipolysis through reduced ATGL protein synthesis; augmented lipolysis by ATGL overexpression restores thermogenesis in adipocyte-specific Chchd10 knockout mice.\",\n      \"method\": \"Adipocyte-specific conditional knockout mice, ATGL overexpression rescue, OXPHOS complex assembly assay, ATP measurement, lipolysis assay\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with ATGL overexpression rescue defining mechanistic pathway, single lab\",\n      \"pmids\": [\"35709007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"During myogenesis, CHCHD10 interacts with TDP-43 in regenerating myofibers and newly differentiated myotubes; Chchd10 knockout mice have normal skeletal muscle development but blunted cold-induced browning of white adipose tissue with markedly reduced UCP1, indicating CHCHD10 is required for cold-induced, mitochondrion-dependent browning.\",\n      \"method\": \"Co-immunoprecipitation in vivo and ex vivo, Chchd10 knockout mice, cold challenge assay, UCP1 Western blot\",\n      \"journal\": \"Cell regeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo Co-IP combined with KO mouse cold challenge, single lab\",\n      \"pmids\": [\"35362877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHCHD10 S59L mutant knock-in mouse hearts show an extensive metabolic rewiring triggered by proteotoxic mtISR before bioenergetic impairment onset: a switch from oxidative to glycolytic metabolism, enhancement of transsulfuration and one-carbon metabolism, and increased NADPH oxidases activating antioxidant responses with heme depletion.\",\n      \"method\": \"CHCHD10 S55L knock-in mouse model, metabolomics, transcriptomics, metabolic flux analysis, temporal disease staging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse model, multi-omics with temporal staging establishing metabolic rewiring precedes OXPHOS dysfunction, multiple orthogonal methods\",\n      \"pmids\": [\"35263592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHCHD10 S59L mutation induces aggregation of resident CHCHD10 protein in isolated mitochondria and simultaneously enhances aggregation of recombinant TDP-43 imported into mitochondria; wild-type CHCHD10 inhibits the growth of TDP-43 aggregates in an in vitro cell-free system, as demonstrated by filter trap assay and atomic force microscopy.\",\n      \"method\": \"In vitro cell-free aggregation assay, isolated mitochondria, filter trap assay, atomic force microscopy, transgenic mice, human brain tissue\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 / Moderate — in vitro reconstitution of aggregation, AFM structural validation, multiple model systems, single lab\",\n      \"pmids\": [\"35787294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHCHD10 amyloid fibrils formed by the disordered N-terminal domain of CHCHD10 have a cryoEM-resolved structure; disease-associated mutations cannot be accommodated by the WT fibril structure, whereas sequence differences between CHCHD10 and CHCHD2 are tolerated, explaining co-aggregation of the two proteins.\",\n      \"method\": \"CryoEM structure determination of amyloid fibrils formed by N-terminal domain of CHCHD10\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryoEM structure of amyloid fibrils with mutant compatibility analysis; single lab but rigorous structural method\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Mutant CHCHD10 S55L causes impaired mitochondrial copper homeostasis and defective cytochrome c oxidation as an early bioenergetic defect; defective respiration in mutant mitochondria is rescued by exogenous addition of cytochrome c, pinpointing IMS proteostasis disruption affecting cytochrome c biogenesis as a key pathogenic mechanism; OMA1 catalytic inactivation in Chchd10 S55L/+ mice delays cardiomyopathy onset without rescuing CHCHD10 insolubility, cristae defects or OXPHOS impairment, demonstrating mtISR can be uncoupled from bioenergetic collapse.\",\n      \"method\": \"CHCHD10 S55L knock-in mice crossed with Oma1 E324Q knock-in mice, cytochrome c rescue assay, copper homeostasis measurements, proteomic profiling of insoluble mitochondrial proteins\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution rescue by exogenous cytochrome c, genetic epistasis with OMA1 catalytic mutant, proteomic profiling, multiple orthogonal methods in single study\",\n      \"pmids\": [\"41420107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHCHD2 and CHCHD10 interact with ATG8-family proteins (preferentially GABARAPs) and with C1QBP/p32 to form a CHCHD2-CHCHD10-C1QBP-ATG8 complex; through GABARAP binding, CHCHD2 and CHCHD10 undergo autophagic degradation and recruit the ULK1 complex; CHCHD2 and CHCHD10 promote autophagy initiation and reduce protein aggregates.\",\n      \"method\": \"Co-immunoprecipitation, iPSC-derived CHCHD2 knockout neurons, autophagy flux assays, ULK1 complex recruitment assay, in vivo α-synuclein aggregate reduction\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP defining multiprotein complex, functional autophagy assays, KO neuronal models, single lab\",\n      \"pmids\": [\"42183628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In mouse tissues, CHCHD2 and CHCHD10 exist exclusively as a high molecular weight complex whose levels are finely tuned; in response to mitochondrial dysfunction, the abundance and size of the CHCHD2-CHCHD10 complex increase, a mechanism conserved across different tissues; loss of CHCHD2 does not abolish CHCHD10 oligomerization but enhances cell vulnerability to mitochondrial stress.\",\n      \"method\": \"Whole-body Chchd2 knockout mouse, BN-PAGE complex analysis, mitochondrial stress treatments across tissues\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse knockout with BN-PAGE complex analysis, stress-response characterization, single lab\",\n      \"pmids\": [\"41053020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nifuroxazide rescues mitochondrial network fragmentation and cristae abnormalities in CHCHD10 S59L/+ patient fibroblasts; the rescue mechanism involves KIF5B-mediated mitochondrial transport enhancement with increased axonal movement and syntaphilin degradation in patient-derived motor neurons.\",\n      \"method\": \"Drug screen in yeast MICOS mutant strains, patient fibroblast rescue assay, iPSC-derived motor neuron live imaging, syntaphilin quantification\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast screen plus patient cell and iPSC rescue with mechanistic transport readout, single lab\",\n      \"pmids\": [\"39478664\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHCHD10 is a nuclear-encoded mitochondrial intermembrane space protein that localizes to cristae junctions as part of the MICOS complex (with mitofilin, CHCHD3, CHCHD6) and forms heterodimers/high-molecular-weight complexes with its paralog CHCHD2; it supports mitochondrial cristae integrity, Complex I and Complex IV (COX) assembly, and efficient oxidative phosphorylation, while also suppressing OMA1 peptidase activity to prevent aberrant OPA1 cleavage and mtISR activation; disease-associated gain-of-function mutations (notably S59L and G58R) cause CHCHD10 to misfold and aggregate, disrupting MICOS/PHB/OPA1-mitofilin complexes, impairing cytochrome c biogenesis, activating the OMA1-DELE1-HRI integrated stress response axis, inducing widespread metabolic rewiring, and promoting TDP-43 aggregation, while haploinsufficiency mutations (R15L, G66V) reduce protein levels and impair Complex I assembly and respiration.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CHCHD10 is a nuclear-encoded mitochondrial intermembrane-space protein, enriched at cristae junctions, that supports cristae architecture and oxidative phosphorylation [#0, #1]. It is imported via Mia40-dependent disulfide-bond formation through its CHCH domain rather than a canonical N-terminal targeting signal, and the ALS variant Q108P blocks import to cause cytoplasmic mislocalization [#5]. Structurally, CHCHD10 is a constituent of the MICOS complex with mitofilin, CHCHD3 and CHCHD6, and forms heterodimers and a ~220 kDa high-molecular-weight complex with its paralog CHCHD2, which exist in vivo essentially exclusively as a finely tuned, stress-responsive HMW assembly [#1, #3, #4, #29]. Functionally, CHCHD10 contributes to Complex I assembly and respiration and to cytochrome c oxidase (Complex IV) activity [#3, #18], with mutant work pinpointing IMS proteostasis and cytochrome c biogenesis (copper-dependent) as early bioenergetic requirements [#27]. Together with CHCHD2, CHCHD10 binds and restrains the OMA1 metallopeptidase to prevent aberrant cleavage of L-OPA1, and the two paralogs are partially functionally redundant; loss of both, or mutant aggregation, activates OMA1, triggering OPA1 processing, cristae disruption and the integrated stress response via DELE1 cleavage [#8, #9, #11]. CHCHD10 also stabilizes the SLP2-prohibitin and OPA1-mitofilin complexes [#10, #13]. Disease-associated mutations act predominantly through gain of toxic function: S59L/S55L and G58R cause CHCHD10 to misfold into amyloid fibrils formed by its disordered N-terminal domain (a structure incompatible with disease mutations but tolerant of CHCHD2 differences, explaining co-aggregation), driving a proteotoxic mitochondrial integrated stress response, metabolic rewiring, and enhanced TDP-43 aggregation, while ablation of CHCHD10 does not reproduce disease pathology [#7, #11, #24, #25, #26]. Distinct haploinsufficiency mutations (R15L, G66V) reduce protein levels and impair Complex I assembly and respiration [#19, #3]. CHCHD10 dysfunction links mitochondrial failure to motor pathology by promoting cytoplasmic TDP-43 accumulation and disrupting PINK1/PARL-dependent mitophagy [#12, #16, #17]. Mutations in CHCHD10 cause FTD/ALS-spectrum disease through these convergent mechanisms [#12, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Established the first functional link between CHCHD10 and the respiratory chain, before its disease relevance was known.\",\n      \"evidence\": \"siRNA knockdown with Complex IV activity assay in vitro\",\n      \"pmids\": [\"20888800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No localization or mechanism defining how CHCHD10 supports COX\", \"Single functional readout\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved where CHCHD10 acts and that a disease mutation has structural consequences, localizing it to the IMS/cristae junctions and showing S59L disrupts the mitochondrial network and cristae.\",\n      \"evidence\": \"Immunofluorescence, subcellular fractionation, S59L overexpression in HeLa with ultrastructural imaging\",\n      \"pmids\": [\"24934289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Overexpression rather than endogenous mutant\", \"Molecular partners undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined CHCHD10's structural context by placing it in the MICOS complex and connecting MICOS disassembly to cristae loss, nucleoid disorganization and altered apoptosis.\",\n      \"evidence\": \"Reciprocal Co-IP, patient fibroblasts, EM, apoptosis assays\",\n      \"pmids\": [\"26666268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect MICOS contact not resolved\", \"mtDNA-repair link mechanistically thin\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected mitochondrial CHCHD10 function to the central ALS/FTD proteinopathy by showing loss of function and dominant-negative mutants drive cytoplasmic TDP-43 accumulation.\",\n      \"evidence\": \"C. elegans complementation, mammalian cells, primary neurons, mouse brains\",\n      \"pmids\": [\"28585542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Loss- vs gain-of-function balance left ambiguous across systems\", \"Molecular route from mitochondria to TDP-43 not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Characterized the CHCHD10-CHCHD2 partnership and the import pathway, showing heterodimer/HMW complex formation, CHCHD2-dependent oligomerization, and Mia40/CHCH-domain-dependent import disrupted by Q108P.\",\n      \"evidence\": \"Reciprocal Co-IP, BN-PAGE, double-knockout cells, Mia40 KD/OE rescue, truncations, interactome MS\",\n      \"pmids\": [\"29112723\", \"29121267\", \"30084972\", \"29789341\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of HMW complex not yet defined\", \"p32/GC1QR interaction role unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Distinguished mutation classes mechanistically, defining R15L/G66V as haploinsufficiency reducing protein and impairing Complex I, versus gain-of-toxic-function variants, and proposing a nuclear transcriptional/COX-scaffolding role.\",\n      \"evidence\": \"Patient cells, zebrafish knockdown, BN-PAGE, COX co-purification, transcriptional reporters\",\n      \"pmids\": [\"29121267\", \"29315381\", \"29540477\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear CXXC5/ORE role not independently replicated\", \"Reconciliation of loss- vs gain-of-function across variants incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established gain-of-toxic-function in vivo and ordered the pathology, showing knock-in (not knockout) mice aggregate CHCHD10 with CHCHD2, induce mtISR via mTORC1, and target muscle before NMJ and motor neurons.\",\n      \"evidence\": \"S55L/S59L knock-in mice with knockout comparison, omics, temporal histopathology, iPSC motor neurons\",\n      \"pmids\": [\"30877432\", \"30874923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger of aggregation in specific tissues unknown\", \"Link between aggregation and mtISR not yet mechanistic\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified the OMA1-OPA1 axis as the effector pathway, showing CHCHD2/CHCHD10 loss activates OMA1 to cleave L-OPA1, that the paralogs are partially redundant, and that TDP-43 lowers CHCHD10 to disassemble OPA1-mitofilin complexes.\",\n      \"evidence\": \"Double-knockout and knock-in mice, OPA1 cleavage/OMA1 assays, Co-IP, fusion/respiration assays, FTLD-TDP brains\",\n      \"pmids\": [\"32338760\", \"32369233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CHCHD10 restrains OMA1 mechanistically not shown\", \"Directness of TDP-43 effect on CHCHD10 unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended CHCHD10 function to peripheral tissue physiology, linking its ATP-generating role to AChR clustering at the NMJ.\",\n      \"evidence\": \"Muscle conditional knockout mice with ATP rescue, AChR clustering and electrophysiology\",\n      \"pmids\": [\"31261376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding\", \"Relationship to mutant pathology not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped the downstream metabolic and stress consequences, showing R15L Complex I deficiency rewires one-carbon/TCA metabolism and AMPK/mTORC1 and triggers ER and mitochondrial UPR, while S59L chronically activates PINK1 with TDP-43 mitochondrial translocation.\",\n      \"evidence\": \"Multi-omics in patient cells; Drosophila/HeLa with PINK1 manipulation and TDP-43 translocation inhibitor\",\n      \"pmids\": [\"33749723\", \"33772006\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal ordering of metabolic vs stress responses incomplete\", \"PINK1 activation mechanism not yet defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Consolidated the mechanism, demonstrating CHCHD2/CHCHD10 directly suppress OMA1 and bind eIF2alpha to limit mtISR, stabilize the SLP2-prohibitin complex, and that OMA1 acts via DELE1 cleavage to drive the ISR essential for mutant-mouse survival.\",\n      \"evidence\": \"Co-IP/OMA1 enzymatic assays, G58R and S59L knock-in mice with OMA1 ablation, DELE1 cleavage assay, omics, EM\",\n      \"pmids\": [\"35173147\", \"35656794\", \"35700042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytosolic eIF2alpha interaction needs independent replication\", \"Stoichiometry of OMA1 suppression unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed proteotoxic mtISR drives metabolic rewiring before bioenergetic failure and defined non-disease metabolic roles in adipocyte browning and lipolysis.\",\n      \"evidence\": \"S55L knock-in heart metabolomics/flux with temporal staging; adipocyte-specific KO with ATGL rescue; KO cold-challenge; in vivo TDP-43 Co-IP\",\n      \"pmids\": [\"35263592\", \"35709007\", \"35362877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How aggregation initiates metabolic rewiring unresolved\", \"Tissue specificity of browning role not generalized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated reconstituted aggregation behavior, showing S59L promotes self- and TDP-43 aggregation in isolated mitochondria/cell-free systems and that WT CHCHD10 suppresses TDP-43 aggregate growth.\",\n      \"evidence\": \"Cell-free aggregation, isolated mitochondria, filter trap, AFM, transgenic mice, human brain\",\n      \"pmids\": [\"35787294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro relevance to in vivo seeding uncertain\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked CHCHD10 to mitophagy quality control, showing WT suppresses PARL to stabilize PINK1 and support Parkin recruitment/mitophagy, while mutants increase PARL activity, impair mitophagy and promote TDP-43 aggregation.\",\n      \"evidence\": \"Co-IP CHCHD10-PARL, PARL activity and mitophagy flux assays, Parkin recruitment, in vivo and human FTD brain\",\n      \"pmids\": [\"38132101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directness of PARL regulation needs confirmation\", \"Reconciliation with PINK1-activation finding from 2021\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided structural basis for aggregation, resolving CHCHD10 N-terminal amyloid fibrils by cryoEM and explaining why disease mutations destabilize the fold while CHCHD2 differences are tolerated, rationalizing co-aggregation.\",\n      \"evidence\": \"CryoEM structure of N-terminal-domain amyloid fibrils (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Preprint, not peer reviewed\", \"Fibril relevance to in vivo aggregates not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a CHCHD2-CHCHD10-C1QBP-ATG8 complex through which the paralogs promote autophagy initiation, recruit ULK1, and reduce protein aggregates.\",\n      \"evidence\": \"Reciprocal Co-IP, iPSC CHCHD2-KO neurons, autophagy flux, ULK1 recruitment, in vivo aggregate reduction\",\n      \"pmids\": [\"42183628\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"How an IMS protein engages cytosolic ATG8 machinery unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Dissected the earliest pathogenic defect and uncoupled stress from bioenergetics, showing impaired copper homeostasis and cytochrome c biogenesis is rescuable by exogenous cytochrome c, while OMA1 catalytic inactivation delays cardiomyopathy without rescuing insolubility, cristae or OXPHOS defects.\",\n      \"evidence\": \"S55L knock-in crossed with Oma1 E324Q mice, cytochrome c rescue, copper measurements, insoluble-proteome profiling\",\n      \"pmids\": [\"41420107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking IMS proteostasis to copper handling unresolved\", \"Therapeutic implications of mtISR/bioenergetics uncoupling untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Characterized the native CHCHD2-CHCHD10 complex as an essentially obligate, stress-tunable HMW assembly conserved across tissues, with CHCHD2 loss sensitizing cells to mitochondrial stress.\",\n      \"evidence\": \"Whole-body Chchd2 KO mouse, BN-PAGE, cross-tissue stress treatments\",\n      \"pmids\": [\"41053020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subunit stoichiometry and additional components undefined\", \"Functional output of complex enlargement unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the disordered N-terminal aggregation seed mechanistically couples to specific downstream effectors (OMA1, PARL/PINK1, TDP-43, copper/cytochrome c biogenesis) to determine tissue-selective vulnerability remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of which effector arm is primary in each affected tissue\", \"No therapeutic target validated in patients\", \"Order of aggregation, mtISR, and bioenergetic failure not fully resolved in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 11, 17]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005758\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 18]},\n      {\"term_id\": \"GO:0005743\", \"supporting_discovery_ids\": [1, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 18, 24]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [7, 11, 9]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 20]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [17, 28]}\n    ],\n    \"complexes\": [\n      \"MICOS complex\",\n      \"CHCHD2-CHCHD10 high-molecular-weight complex\",\n      \"SLP2-prohibitin (PHB) complex\",\n      \"CHCHD2-CHCHD10-C1QBP-ATG8 complex\"\n    ],\n    \"partners\": [\n      \"CHCHD2\",\n      \"OMA1\",\n      \"PARL\",\n      \"C1QBP\",\n      \"SLP2\",\n      \"TDP-43\",\n      \"CXXC5\",\n      \"GABARAP\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}